Additionally, research has found that risk scores constructed based on cuproptosis-related genes correlate with immune checkpoint molecules, such as PD-L1, CTLA4, targeted therapy-related genes, cancer stem cell characteristics, and sensitivity to chemotherapy and targeted drugs (52). This evidence concerns the gene CTLA4 and cancer.